Literature DB >> 16337421

A CD14 monocyte receptor polymorphism and genetic susceptibility to Parkinson's disease for females.

J J Lin1, C H Chen, K C Yueh, C Y Chang, S Z Lin.   

Abstract

Recent studies suggest that inflammation may play an important role in the pathogenesis of Parkinson's disease (PD). Because the C(-260) --> T polymorphism in the promoter of the CD14 monocyte receptor gene (pCD14) could affect the predisposition to the inflammatory response, we conducted a case-control study to investigate a possible genetic susceptibility of the pCD14 polymorphism in patients with PD. This study included 200 sporadic PD patients and 200 controls, matched by sex and case-control pairs for age at onset in the case. All observed genotype frequencies were in Hardy-Weinberg equilibrium. Results revealed that the CD14-T allele of the pCD14 polymorphism in the female PD patients existed statistically significant difference from that of the female controls (OR = 1.262, P = 0.038), but not for male. Female individuals with homozygote CD14-TT genotype were significantly increased risk of PD by 1.28 time (P = 0.027). Furthermore, a logistic regression analysis confirmed that the homozygote CD14-TT genotype was an independent risk factor for PD (OR = 1.576, P = 0.030). In conclusion, results of this study indicate the pCD14 polymorphism to be a genetic risk factor for PD in females.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16337421     DOI: 10.1016/j.parkreldis.2005.07.010

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  9 in total

1.  VKORC1 and CD-14 genetic polymorphisms associate with susceptibility to cardiovascular and cerebrovascular diseases.

Authors:  Jian Du; Zhiguo Zhang; Yuanyuan Ge; Juan Zhen; Jiyan Leng; Jianmeng Wang
Journal:  Int J Clin Exp Med       Date:  2015-11-15

2.  Association of CD14-260 (-159) C/T and Alzheimer's disease: systematic review and trial sequential analyses.

Authors:  Yan Wang; Xiaoling Wu; Xun Deng; Yanjiao Ma; Siyi Huang; Yong Wang
Journal:  J Neural Transm (Vienna)       Date:  2018-06-20       Impact factor: 3.575

Review 3.  The relevance of gender in Parkinson's disease: a review.

Authors:  Marina Picillo; Alessandra Nicoletti; Vincenza Fetoni; Barbara Garavaglia; Paolo Barone; Maria Teresa Pellecchia
Journal:  J Neurol       Date:  2017-01-04       Impact factor: 4.849

Review 4.  The role of inflammation in sporadic and familial Parkinson's disease.

Authors:  Michela Deleidi; Thomas Gasser
Journal:  Cell Mol Life Sci       Date:  2013-05-12       Impact factor: 9.261

5.  Absence of CD14 delays progression of prion diseases accompanied by increased microglial activation.

Authors:  Keiko Sakai; Rie Hasebe; Yusuke Takahashi; Chang-Hyun Song; Akio Suzuki; Takeshi Yamasaki; Motohiro Horiuchi
Journal:  J Virol       Date:  2013-10-02       Impact factor: 5.103

6.  The endotoxin-induced neuroinflammation model of Parkinson's disease.

Authors:  Kemal Ugur Tufekci; Sermin Genc; Kursad Genc
Journal:  Parkinsons Dis       Date:  2011-01-18

7.  Common gene-network signature of different neurological disorders and their potential implications to neuroAIDS.

Authors:  Vidya Sagar; S Pilakka-Kanthikeel; Paola C Martinez; V S R Atluri; M Nair
Journal:  PLoS One       Date:  2017-08-08       Impact factor: 3.240

Review 8.  Supramolecular organizing centers at the interface of inflammation and neurodegeneration.

Authors:  Petra Sušjan-Leite; Taja Železnik Ramuta; Elvira Boršić; Sara Orehek; Iva Hafner-Bratkovič
Journal:  Front Immunol       Date:  2022-08-01       Impact factor: 8.786

9.  Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease.

Authors:  Carmen Noelker; Lydie Morel; Thomas Lescot; Anke Osterloh; Daniel Alvarez-Fischer; Minka Breloer; Carmen Henze; Candan Depboylu; Delphine Skrzydelski; Patrick P Michel; Richard C Dodel; Lixia Lu; Etienne C Hirsch; Stéphane Hunot; Andreas Hartmann
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.